

Adult Participants needed for Clinical Study of ATR-101 for the Treatment of Classic Congenital Adrenal Hyperplasia (CAH) – Male and female adult volunteers with classic CAH, ages 18-80, are needed for an ongoing clinical trial of the investigational compound, ATR-101. Millendo Therapeutics is conducting a single-blind, multiple dose study to assess the effect of ATR-101 on adrenal hormone levels and safety measures in adult patients with classic CAH. A participant may receive a minimum of one dose level or up to a maximum of 5 dose levels of ATR-101, in sequentially increasing dose strengths. Each dose level will last 28 days. Participants will continue their current CAH treatment during the course of the study.

The study will include 9-17 participants at the following 6 clinical sites in the United States:

Johns Hopkins University
Baltimore, Maryland
Principal Investigator: Roberto Salvatori, MD
Contact: Oyinkan Kusemiju 410-955-2812 okusemi1@jhmi.edu

National Institutes of Health Clinical Center
Bethesda, Maryland
Principal Investigator: Deborah Merke, MD
Contact: Elizabeth Joyal 301-496-8542 ejoyal@mail.nih.gov

University of Michigan
Ann Arbor, Michigan
Principal Investigator: Richard Auchus, MD
Contact: Timothy Muth 734-615-8914 tmuth@ed.umich.edu

Mayo Clinic – Rochester
Rochester, Minnesota
Principal Investigator: Alice Chang, MD
Contact: Samantha McAllister 507-266-3912 McAllister.Samantha@may.edu

The University of Oklahoma - Tulsa Schusterman Center
Tulsa, Oklahoma
Principal Investigator: Laura Chalmers, MD
Contact: Sharnella Goudeau 918-619-4803 sharnella-goudeau@ouhsc.edu

The Children's Hospital of Philadelphia
Philadelphia, Pennsylvania
Principal Investigator: Maria Vogiatzi, MD
Contact: Michelle Pitt 215-590-3174 pittm@email.chop.edu

Persons interested in participating can also find more information at www.ClinicalTrials.gov (NCT02804178).